Document:

EXHIBIT 10.21

        SECOND AMENDMENT TO

        DISTRIBUTION AGREEMENT

        FOR FLUVIRALTM (INFLUENZA VACCINE)

         

        THIS SECOND AMENDMENT is entered into as of the 5th day of October, 2006, by and between ID Biomedical Corporation (“IDB”) and Henry Schein, Inc.(“HSI”) (the “Second Amendment”).

         

        WHEREAS, HSI and IDB have entered into a certain Distribution Agreement for FluviralTM influenza vaccine as of December 2, 2004, as amended by the Amendment effective October 2, 2006 (“Agreement”);

         

        WHEREAS, HSI and IDB desire to further amend certain terms of the Amendment for the 2006/2007 Flu Season only;

         

        NOW, THEREFORE, in consideration of the mutual covenants contained hereto, the parties, intending to be legally bound, agree to further amend the Amendment that applies to the 2006/2007 Flu Season only as follows:

         

        1.        The next to the last sentence of subparagraph (a) of the revised Section 3.1 of the Amendment is hereby deleted and restated in its entirety as follows:

         

        “HSI hereby agrees to provide distribution services in connection with the sales of such doses and to charge the end use customer no more than the price negotiated by IDB with the end user customer (HSI may charge less if it elects to do so), and HSI shall pay IDB for such doses the Purchase Price set forth in Section 2(A)(v) of Schedule 1 of the Agreement, provided that HSI’s
        obligation to pay IDB the Purchase Price for such doses shall be contingent on HSI’s receipt of payment from the end user customer for the doses.”

         

        2.         The second sentence of subparagraph 3.1 (b) is deleted and restated in its entirety as follows:

         

        “Any written notice from HSI must specify the amount of Product it elects to purchase for delivery and release in November and a requested delivery schedule that is consistent with the estimated delivery schedule described in subsection (a) above, and IDB shall use commercially reasonable efforts to distribute product in accordance with such proposed delivery schedule, provided that
        any Product which IDB fails to deliver in accordance with the proposed delivery schedule shall be returnable to IDB for full refund.”

         

        3.         The next to the last sentence of subparagraph (b) of the revised Section 3.1 of the Amendment is hereby deleted and restated in its entirety as follows:

         

        
            

        

         

        “In the event that such doses are available for delivery and release in November or December and IDB is able to find a purchaser for such doses and requires distribution services, HSI hereby agrees to provide distribution services in connection with the sales of such doses and to charge the end use customer no more than the price negotiated by IDB with the end user customer (HSI may
        charge less if it elects to do so), and HSI shall pay IDB for such doses the Purchase Price set for in Section 2(A)(v) of Schedule 1 of the Agreement, provided that HSI’s obligation to pay IDB the Purchase Price for such doses shall be contingent on HSI’s receipt of payment from the end user customer for the doses.”

         

        
            	
                        4.

                    	
                        Section 4.1 is amended to add the following sentence to the end thereof:

                    

        

         

        “During the 2006/2007 Flu season only, General Injectables & Vaccines, Inc. (“GIV”), a wholly-owned subsidiary of HSI, shall be billed for Product delivered hereunder and HSI shall cause GIV to pay all such bills due and owing.”

         

        5.         The following words are inserted in line 12 of the revised subparagraph (b) of Schedule 1 to the Amendment after the term “October 31, 2006”.

         

        “(the “October Doses”)”

         

        6.         The following new sentence is added to the end of the revised subparagraph (b) of Schedule 1 to the Amendment:

         

        “Notwithstanding anything to the contrary contained in the Agreement, any October Doses that are not delivered to HSI’s warehouses and released for sale by October 31, 2006 shall be returnable to IDB for full refund.”

         

        
            	
                        7.

                    	
                        The following new provision 5.6 is added for the 2006/2007 Flu season only:

                    

        

         

        “HSI desires and GSK agrees to ship to HSI designated locations other than the HSI warehouse and in exchange for GSK shipping to the other HSI designated locations, HSI agrees to pay the accrual shipping costs not to exceed five thousand dollars ($5,000.00) per week for such shipments.”

         

        All remaining terms and conditions of the Agreement as amended not expressly amended herein shall remain in full force and effect.

         

        In the event of a conflict between any of the terms contained in this Second Amendment and the terms contained in the Agreement, the terms of the Second Amendment shall govern.

         

        All defined terms and conditions not expressly defined herein shall have the meaning ascribed to such terms in the Agreement.

         

        
            

        

         

        IN WITNESS WHEREOF, the parties have executed this Amendment as of the date last written below.

        
            	
                        ID Biomedical Corporation

                    	
                        Henry Schein, Inc.

                    

        

         

         

         

        
            	
                        By:

                    	
                        /s/ Paul Pinsonnault

                    	
                        By:

                    	
                        /s/ Philip Baseil

                    
	
                        Title

                    	
                        Secretary

                    	
                        Title

                    	
                        VP Business Development

                    
	
                        Date

                    	
                        November 3, 2006

                    	
                        Date

                    	
                        10/25/06EXHIBIT 10.22

        AMENDMENT TO DISTRIBUTION AGREEMENT

         

        This Amendment (this “Amendment”) is entered into as of December 20, 2007, by and between ID Biomedical Corporation (“IDB”) and Henry Schein, Inc. (“HSI”).

         

        HSI and IDB have entered into a certain Distribution Agreement for Fluviral influenza and vaccine as of December 2, 2004 and have entered into certain amendments to that agreement from time to time (as amended, the “Agreement”). In December 2005, IDB became a wholly owned subsidiary of GlaxoSmithKline Inc., a wholly owned subsidiary of GlaxoSmithKline plc and an affiliate of
        SmithKline Beecham Corporation d/b/a GlaxoSmithKline (“GSK”). HSI and IDB desire to make certain amendments to the Agreement as set forth herein, including a clarification regarding a dispute of the appropriate interpretation of the Agreement with respect to payments by HSI to IDB of the Federal excise tax, currently in the amount of $0.75 per dose, levied against the sale of flu vaccine in the United States.

         

        NOW THEREFORE, in consideration of the mutual covenants and agreements contained herein, and upon the terms and subject to conditions set forth below, HSI and IDB, intending to be legally bound hereby, agree to amend the Agreement as follows:

         

        1.                         Definitions. All capitalized terms used in this Amendment without definition shall have the meanings set forth in the Agreement.

         

        2.                      Federal Excise Tax. Section 4.1 is hereby amended, for the 2007/2008 Flu Season, by adding the following sentences at the end thereof: “For purposes of clarification, in
        addition to the Purchase Price, HSI shall also pay to IDB for all Product shipped to HSI for the 2007/2008 Flu Season all applicable Federal excise taxes on all Product shipped to HSI in effect on the date of IDB’s shipment of Product to HSI; and any such Federal excise tax shall not be included in the calculation of the Net Sales Revenue either as amounts invoiced or as a reduction of the gross amounts invoiced. In the event that any Product sold to HSI on which HSI has paid IDB
        the Federal excise tax is not used in the 2007/2008 Flu Season by a customer of HSI (or not sold by HSI), HSI may return such Product to IDB’s designated location for such returns and IDB will seek reimbursement for the Federal excise tax paid by HSI from the Federal government and will pay any such reimbursement to HSI. Any such return or reimbursement will not include a refund or reimbursement by IDB of the Purchase Price of such Product. In the event that the laws, rules or
        regulations governing the Federal excise tax change from time to time, the parties will negotiate in good faith reasonable amendments to the Agreement to address those changes consistent with this provision.”

         

        3.                      Effect of Amendment. Except as expressly modified by this Amendment, the terms and provisions of the Agreement shall remain in full force and effect. In the event of any conflict between the terms of this Amendment and
        the terms of the Agreement, the terms of this Amendment shall control.

         

        
            

        

         

        4.                      Miscellaneous. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be reasonably necessary or appropriate in order to carryout the purposes and intent of
        this Amendment.

         

        5.                      Counterparts. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.

         

         

        IN WITNESS WHEROF, each Party has caused this Amendment to the Agreement to be executed on its behalf by its duly authorized office as of the date first above written.

         

        
            	
                        ID Biomedical Corporation

                    	
                        Henry Schein, Inc.

                    

        

         

                                         

        
            	
                        By:

                    	
                        /s/ Kurt Henjes

                    	
                        By:

                    	
                        /s/ Philip A. Baseil

                    
	
                        Title:

                    	
                        Director

                    	
                        Title:

                    	
                        V.P. Vendor Relations

                    
	
                         

                    	
                         

                    	
                         

                    	
                        Henry Schein Inc., Medical

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}]]